Suppr超能文献

成功治疗三例严重耐多药或广泛耐药铜绿假单胞菌感染的头孢他啶/他唑巴坦。

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.

机构信息

Infectious Diseases Department, Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.

Microbiology Department, Hospital Clínic-ISGLOBAL; University of Barcelona, Barcelona, Spain.

出版信息

Future Microbiol. 2017 Nov;12:1323-1326. doi: 10.2217/fmb-2017-0018. Epub 2017 Oct 5.

Abstract

Ceftolozane/tazobactam is a novel fifth-generation cephalosporin β-lactamase combination with activity against extended-spectrum β-lactamases-producing enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. However, clinical experience in real cases caused by these microorganisms is scarce. In this study, we describe three patients with severe infections caused by multidrug resistant and extensively drug-resistant (XDR) P. aeruginosa that were successfully treated with ceftolozane/tazobactam.

摘要

头孢洛扎他唑巴坦是一种新型第五代头孢菌素β-内酰胺酶抑制剂复合制剂,对产超广谱β-内酰胺酶的肠杆菌科和多重耐药铜绿假单胞菌具有活性。然而,针对这些微生物引起的真实病例的临床经验还很有限。在本研究中,我们描述了 3 例由多重耐药和广泛耐药(XDR)铜绿假单胞菌引起的严重感染患者,他们使用头孢洛扎他唑巴坦治疗获得了成功。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验